$CGRA The Company continues to stay focused on expansion plans of its Washington state cannabis facility, securing necessary growth funding, and making progress on its’ NutriLife CBD business launch. Towards that end, the Company included in its business development plans the inclusion of strategic partners and the production of Delta-8 products. Delta-8 is a naturally occurring cannabinoid and derived from hemp, but unlike Delta-9 (THC), it is legalized in the 2018 Farm Bill and it is not prohibited under federal law.

In addition to pressing forward on cannabis and hemp initiatives, the Company, as part of a strategy to streamline, will be working to divest certain balance sheet neutral assets that have limited our ability to complete audits and position ourselves for uplisting to a fully reporting company. With that in mind, certain non-performing foreign and domestic assets will be divested to reduce our overall debt load and exposure to market fluctuation. The moves will pave the way for efficient auditing and reporting. Further details will be provided as final decisions and arrangements have been made. https://finance.yahoo.com/news/cgrowth-capita...00336.html